CIK 0001599901
RNA Avidity Biosciences, Inc.
Insider trading from SEC Form 4. Last filing Feb 27, 2026. Close $8.40 on Oct 9, 2026, +7% from the 52-week low and -49% from the high.
Avidity Biosciences, Inc. (RNA) has 107 SEC Form 4 filings on file from 17 insiders, the latest filed on Feb 27, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
65 open-market trades have been scored at RNA. The newest: Teresa McCarthy (Chief Human Resources Officer) sold $212k of stock on Jan 21, 2026, filed Jan 23, 2026, scored 22 (weak), under a 10b5-1 plan. The largest of the 50 shown: Eric Mosbrooker (Chief Commercial Officer) sold $5.8M on Aug 6, 2025, scored 40 (moderate), under a 10b5-1 plan. 8 insiders sold within 14 days of each other around Jan 21, 2026.
RNA closed at $8.40 on Oct 9, 2026, 7% above its 52-week low and 49% below its 52-week high.
24 Form 144 notices of planned sales are on file, the latest filed Sep 11, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
17
with a Form 4 at this company
Price and insider trades, last year
RNAOct 9, 2026 · close 8.40
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Avidity Biosciences, Inc., scored: the newest 50 of 65.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | Teresa McCarthy Chief Human Resources Officer sell | $212k 2,929 shares | -3% | - | |
| 21Weak | Arthur A Levin director sell | $127k 1,758 shares | -10% | - | |
| 32Weak | Michael F MacLean Chief Financial Officer sell | $329k 4,542 shares | -7% | - | |
| 27Weak | W. Michael Flanagan Chief Scientific Officer sell | $473k 6,534 shares | -7% | - | |
| 45Moderate | Sarah Boyce President and CEO sell | $1.0M 14,387 shares | -5% | - | |
| 30Weak | Steven George Hughes Chief Medical Officer sell | $355k 4,895 shares | -13% | - | |
| 21Weak | W. Michael Flanagan Chief Scientific Officer sell | $171k 2,373 shares | -3% | - | |
| 21Weak | Steven George Hughes Chief Medical Officer sell | $171k 2,373 shares | -6% | - | |
| 28Weak | Michael F MacLean Chief Financial Officer sell | $143k 1,974 shares | -3% | - | |
| 21Weak | John B Moriarty Chief Legal Officer sell | $171k 2,374 shares | -3% | - | |
| 21Weak | Teresa McCarthy Chief Human Resources Officer sell | $142k 1,965 shares | -2% | - | |
| 23Weak | Charles Calderaro III Chief Technical Officer sell | $269k 3,727 shares | -7% | - | |
| 40Moderate | Sarah Boyce President and CEO sell | $619k 8,576 shares | -3% | - | |
| 0Weak | Steven George Hughes Chief Medical Officer sell | $105k 2,209 shares | -5% | - | |
| 25Weak | Teresa McCarthy Chief Human Resources Officer sell | $1.0M 20,000 shares | -17% | - | |
| 14Weak | Eric Mosbrooker Chief Commercial Officer sell | $298k 6,562 shares | -11% | - | |
| 4Weak | Steven George Hughes Chief Medical Officer sell | $90k 2,208 shares | -5% | - | |
| 3Weak | Steven George Hughes Chief Medical Officer sell | $70k 1,542 shares | -4% | - | |
| 20Weak | Teresa McCarthy Chief Human Resources Officer sell | $621k 15,000 shares | -13% | - | |
| 22Weak | W. Michael Flanagan Chief Scientific Officer sell | $779k 20,000 shares | -20% | - | |
| 30Weak | Troy Edward Wilson director sell | $1.5M 29,500 shares | -35% | - | |
| 14Weak | Eric Mosbrooker Chief Commercial Officer sell | $309k 6,563 shares | -11% | - | |
| 35Weak | Sarah Boyce President and CEO sell | $2.5M 50,000 shares | -14% | - | |
| 10Weak | Kathleen P. Gallagher Chief Program Officer sell | $8,915 188 shares | -0% | - | |
| 30Weak | Sarah Boyce President and CEO sell | $1.2M 25,000 shares | -8% | - | |
| 5Weak | Steven George Hughes Chief Medical Officer sell | $102k 2,208 shares | -5% | - | |
| 3Weak | Steven George Hughes Chief Medical Officer sell | $72k 1,542 shares | -4% | - | |
| 52Moderate | Michael F MacLean Chief Financial Officer sell | $1.3M 30,914 shares | -32% | - | |
| 12Weak | Teresa McCarthy Chief Human Resources Officer sell | $466k 10,000 shares | -9% | - | |
| 40Moderate | Steven George Hughes Chief Medical Officer sell | $3.5M 81,434 shares | -97% | - | |
| 40Moderate | Arthur A Levin director sell | $5.1M 107,500 shares | -85% | - | |
| 40Moderate | Troy Edward Wilson director sell | $4.3M 95,054 shares | -104% | - | |
| 40Moderate | Eric Mosbrooker Chief Commercial Officer sell | $5.8M 130,807 shares | -70% | - | |
| 19Weak | John B Moriarty Chief Legal Officer sell | $81k 2,245 shares | -4% | - | |
| 8Weak | Kathleen P. Gallagher Chief Program Officer sell | $28k 911 shares | -2% | - | |
| 13Weak | W. Michael Flanagan Chief Scientific Officer sell | $658k 20,000 shares | -20% | - | |
| 5Weak | Kathleen P. Gallagher Chief Program Officer sell | $191k 5,875 shares | -10% | - | |
| 0Weak | Kathleen P. Gallagher Chief Program Officer sell | $190k 5,875 shares | -10% | - | |
| 11Weak | Kathleen P. Gallagher Chief Program Officer sell | $163k 5,875 shares | -10% | - | |
| 23Weak | Teresa McCarthy Chief Human Resources Officer sell | $242k 7,778 shares | -7% | - | |
| 30Weak | Michael F MacLean Chief Financial Officer sell | $246k 7,935 shares | -8% | - | |
| 30Weak | W. Michael Flanagan Chief Scientific Officer sell | $366k 11,780 shares | -13% | - | |
| 45Moderate | Sarah Boyce President and CEO sell | $980k 31,540 shares | -9% | - | |
| 29Weak | Steven George Hughes Chief Medical Officer sell | $297k 9,578 shares | -12% | - | |
| 19Weak | W. Michael Flanagan Chief Scientific Officer sell | $603k 20,000 shares | -18% | - | |
| 4Weak | Kathleen P. Gallagher Chief Program Officer sell | $173k 5,875 shares | -10% | - | |
| 12Weak | Kathleen P. Gallagher Chief Program Officer sell | $189k 5,875 shares | -10% | - | |
| 20Weak | Steven George Hughes Chief Medical Officer sell | $113k 3,947 shares | -5% | - | |
| 29Weak | Kathleen P. Gallagher Chief Program Officer sell | $278k 9,411 shares | -16% | - | |
| 34Weak | Sarah Boyce President and CEO sell | $297k 10,397 shares | -3% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 11, 2025 | WILLIAM MICHAEL FLANAGAN Officer | 20,000 0.02% of outstanding | $928k | Sep 11, 2025 | none |
| Sep 5, 2025 | SARAH BOYCE Director, Officer | 50,000 0.04% of outstanding | $2.4M | Sep 5, 2025 | $1.2M |
| Sep 5, 2025 | WILSON TROY EDWARD Chairman | 95,052 0.07% of outstanding | $4.8M | Sep 5, 2025 | $4.3M |
| Sep 3, 2025 | ERIC MOSBROOKER Officer | 19,688 0.02% of outstanding | $930k | Sep 3, 2025 | $5.8M |
| Aug 28, 2025 | SARAH BOYCE Director, Officer | 25,000 0.02% of outstanding | $1.2M | Aug 28, 2025 | none |
| Aug 15, 2025 | TERESA MCCARTHY Officer | 45,000 0.03% of outstanding | $2.1M | Aug 15, 2025 | none |
| Aug 13, 2025 | STEVEN GEORGE HUGHES Officer | 9,709 0.01% of outstanding | $449k | Aug 13, 2025 | $3.5M |
| Aug 6, 2025 | MICHAEL MACLEAN Officer | 30,914 0.03% of outstanding | $1.2M | Aug 6, 2025 | none |
| Aug 6, 2025 | ARTHUR LEVIN Director | 107,500 0.09% of outstanding | $4.1M | Aug 6, 2025 | none |
| Aug 6, 2025 | STEVEN GEORGE HUGHES Officer | 81,434 0.07% of outstanding | $3.1M | Aug 6, 2025 | none |
| Aug 6, 2025 | ERIC MOSBROOKER Officer | 130,807 0.11% of outstanding | $5.0M | Aug 6, 2025 | none |
| Aug 6, 2025 | WILSON TROY EDWARD Chairman | 95,054 0.08% of outstanding | $4.3M | Aug 6, 2025 | none |
| Jun 17, 2025 | KATHLEEN GALLAGHER Officer | 911 0.00% of outstanding | $27k | Jun 17, 2025 | $545k |
| Jun 11, 2025 | WILLIAM MICHAEL FLANAGAN Officer | 20,000 0.02% of outstanding | $672k | Jun 11, 2025 | $366k |
| Jun 2, 2025 | KATHLEEN GALLAGHER Officer | 5,875 0.00% of outstanding | $182k | Jun 2, 2025 | $527k |
| May 1, 2025 | KATHLEEN GALLAGHER Officer | 5,875 0.00% of outstanding | $192k | May 1, 2025 | $525k |
| Mar 11, 2025 | WILLIAM MICHAEL FLANAGAN Officer | 20,000 0.02% of outstanding | $601k | Mar 11, 2025 | $162k |
| Feb 3, 2025 | KATHLEEN GALLAGHER Officer | 17,625 0.01% of outstanding | $580k | Feb 3, 2025 | $278k |
| Jan 22, 2025 | KATHLEEN GALLAGHER Officer | 6,924 0.01% of outstanding | $214k | Jan 22, 2025 | none |
| Dec 16, 2024 | TERESA MCCARTHY Officer | 25,000 0.02% of outstanding | $812k | Dec 16, 2024 | $2.8M |
| Dec 11, 2024 | W. MICHAEL FLANAGAN Officer | 24,000 0.02% of outstanding | $866k | Dec 11, 2024 | $3.5M |
| Nov 6, 2024 | MICHAEL MACLEAN Officer | 106,319 0.10% of outstanding | $4.8M | Nov 6, 2024 | none |
| Oct 21, 2024 | ARTHUR A LEVIN Director | 8,323 0.01% of outstanding | $420k | Oct 21, 2024 | $455k |
| Oct 16, 2024 | LEVIN ARTHUR A Officer | 22,500 0.02% of outstanding | $1.0M | Oct 16, 2024 | $680k |
Transactions
The newest 50 of 323 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | W. Michael Flanagan Chief Scientific Officer | DDisposition to issuer Common Stock | -150,365 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Teresa McCarthy Chief Human Resources Officer | DDisposition to issuer Common Stock | -165,296 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Troy Edward Wilson director | DDisposition to issuer Common Stock | -65,091 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | John B Moriarty Chief Legal Officer | DDisposition to issuer Common Stock | -92,054 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Edward M. Kaye MD director | DDisposition to issuer Common Stock | -6,692 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Carsten Boess director | DDisposition to issuer Common Stock | -6,692 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Kathleen P. Gallagher Chief Program Officer | DDisposition to issuer Common Stock | -80,303 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Noreen Henig director | DDisposition to issuer Common Stock | -6,692 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Sarah Boyce President and CEO | DDisposition to issuer Common Stock | -474,861 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Simona Skerjanec director | DDisposition to issuer Common Stock | -6,692 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Arthur A Levin director | DDisposition to issuer Common Stock | -16,562 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Steven George Hughes Chief Medical Officer | DDisposition to issuer Common Stock | -115,857 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Charles Calderaro III Chief Technical Officer | DDisposition to issuer Common Stock | -98,547 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Eric Mosbrooker Chief Commercial Officer | DDisposition to issuer Common Stock | -79,413 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Jean Jinsun Kim director | DDisposition to issuer Common Stock | -6,692 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Tamar Thompson director | DDisposition to issuer Common Stock | -6,692 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Michael F MacLean Chief Financial Officer | DDisposition to issuer Common Stock | -133,977 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Steven George Hughes Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -73,342 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Noreen Henig director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,034 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Simona Skerjanec director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,034 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Eric Mosbrooker Chief Commercial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -177,188 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | John B Moriarty Chief Legal Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Charles Calderaro III Chief Technical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Kathleen P. Gallagher Chief Program Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,321 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Arthur A Levin director | DDisposition to issuer Common Stockindirect: By family trust | -131,372 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | W. Michael Flanagan Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Michael F MacLean Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -92,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Tamar Thompson director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,034 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Edward M. Kaye MD director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,034 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Jean Jinsun Kim director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,034 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Troy Edward Wilson director | DDisposition to issuer Common Stockindirect: By family trust | -13,711 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Teresa McCarthy Chief Human Resources Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -106,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Sarah Boyce President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -386,015 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Carsten Boess director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,034 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Carsten Boess director | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,489 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Tamar Thompson director | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,489 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Noreen Henig director | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,489 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Steven George Hughes Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -74,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | John B Moriarty Chief Legal Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -160,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Eric Mosbrooker Chief Commercial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | W. Michael Flanagan Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -66,500 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Kathleen P. Gallagher Chief Program Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,829 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Sarah Boyce President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -300,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Arthur A Levin director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,034 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Teresa McCarthy Chief Human Resources Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -65,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Michael F MacLean Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -131,250 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Simona Skerjanec director | DDisposition to issuer Stock Option (Right to Buy)derivative | -42,308 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Troy Edward Wilson director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,034 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Jean Jinsun Kim director | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,489 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | Edward M. Kaye MD director | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,489 | - | - | 0 | Feb 27, 2026 |
50 of 323 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Carsten Boessdirector
- Sarah BoycePresident and CEO
- Charles Calderaro IIIChief Technical Officer
- W. Michael FlanaganChief Scientific Officer
- Kathleen P. GallagherChief Program Officer
- Noreen Henigdirector
- Steven George HughesChief Medical Officer
- Edward M. Kaye MDceo, officer, director
- Jean Jinsun Kimdirector
- Arthur A Levindirector
- Michael F MacLeanChief Financial Officer
- Teresa McCarthyChief Human Resources Officer
- John B MoriartyChief Legal Officer
- Eric MosbrookerChief Commercial Officer
- Simona Skerjanecdirector
- Tamar Thompsondirector
- Troy Edward Wilsonceo, president, officer, director
Questions about RNA
Answered from the filings on this page, as of the latest one.
Are insiders buying RNA?
No. In the last 90 days no insider at Avidity Biosciences, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade RNA on the open market?
Teresa McCarthy (Chief Human Resources Officer) sold $212k of RNA on Jan 21, 2026 and filed the Form 4 on Jan 23, 2026. InsiderTell scored 22 (weak), under a 10b5-1 plan, with 8 insiders on the same side within 14 days.
How many insiders file Form 4 at Avidity Biosciences, Inc.?
17 people have filed a Form 4 at Avidity Biosciences, Inc., among them Carsten Boess (director), Sarah Boyce (President and CEO), Charles Calderaro III (Chief Technical Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.